Trials and Fibrillations with Dr John Mandrola

 
 

Trials and Fibrillations with Dr John Mandrola

  • Why I've Changed My Mind About Shared Decision-Making Shared decision-making is too often an excuse for dubious care, leading this cardiologist to have a change of heart.
  • HRS 2022 Taking Cardiac Pacing From Boring to Super-Cool Ablation has hogged the electrophysiology spotlight recently, but three presentations at the 2022 Heart Rhythm Society meeting put cardiac pacing on the comeback trail.
  • ACC 2022 Sodium Restriction in Heart Failure: Another Dogma Felled If you still think that strict sodium limits are worthwhile in patients with heart failure, the onus is on you to prove it. They have enough to deal with, writes John Mandrola, MD.
  • ACC 2022 Percutaneous Left Atrial Appendage Occlusion: Promise vs Reality The selling point of percutaneous left atrial appendage occlusion is to prevent stroke while avoiding the bleeding risk of antithrombotics. The data paint a different picture, writes John Mandrola, MD.
  • ACC 2022 Mavacamten in HCM: Reasons for Optimism and Caution The novel drug helped patients avoid septal reduction therapy in the short term and approval looks likely, but more details and longer-term safety data will be needed before broader use, writes John Mandrola, MD.
  • ACC 2022 Mandrola Previews ACC 2022 Studies on sodium restriction, fractional flow reserve, and strategies to improve patient and clinician behavior intrigue, but the best part of ACC22 is that it's largely in-person, writes John Mandrola, MD.
  • CardioMEMS Remote HF Monitoring: Resist the Spin and FOMO An expanded indication based on a dubious post hoc analysis of GUIDE-HF should not allow the CardioMEMS HF system to become the therapeutic fashion, writes John Mandrola, MD.
  • Mandrola's Top 10 Cardiology Stories of 2021 Obesity drugs had a good year, the SGLT2 inhibitors stalled, and Entresto looks less impressive -- these are some of the takes from John Mandrola, MD, in his annual review of cardiology research.
  • AHA 2021 PCI vs CABG for Left Main CAD: A Never-Ending Debate? Controversies surrounding the EXCEL trial left questions about the data on stents vs bypass surgery in left main CAD. John Mandrola, MD, reviews a new independent meta-analysis presented at the 2021 AHA.
  • AHA 2021 Early Surgery in Asymptomatic AS Should Wait Another trial favoring early surgery in patients with asymptomatic aortic stenosis is still not enough to change practice, argues this cardiologist.
  • AHA 2021 Questions Remain on Tricuspid Repair at Time of Mitral Surgery The Cardiothoracic Surgical Trials Network trial on repair of mild-to-moderate tricuspid regurgitation in patients undergoing mitral valve surgery leaves this cardiologist with more questions than answers.
  • AHA 2021 Mandrola Previews the Virtual AHA 2021 Trials on aortic stenosis, atrial fibrillation, and a pragmatic use of EHRs are among the picks from this year's American Heart Association scientific sessions.
  • The MI–Mortality Mismatch: When Lowering MI Doesn't Extend Life An analysis challenges the notion that cardiovascular therapies that lower myocardial infarction extend survival. John Mandrola, MD, sees lessons for clinicians, patients, and researchers.
  • ESC 2021 Ablate-and-Pace Delivers a Huge Win for Those Sick With AF In terms of clinical practice, the APAF-CRT trial was the standout from ESC for this electrophysiologist.
  • ESC 2021 Lessons on AF Screening From the LOOP Study Screening for AF with an implantable monitor was not associated with lower stroke or systemic embolism overall, but the AF threshold was low and usual care was excellent, notes John Mandrola, MD.
  • ESC 2021 Incremental, Not Monumental, Win for Empagliflozin in HFpEF The modest effects compel clinicians to be selective in the use of this costly drug, but there will be subgroups of patients who may benefit more, says John Mandrola, MD.
  • ESC 2021 Mandrola Previews ESC 2021 A potential breakthrough in HFpEF, loop monitoring, a novel ablation strategy, and the saddest trial are highlighted by John Mandrola, MD, in his preview of the 2021 European Society of Cardiology sessions.
  • HRS 2021 The Three Big Stories From HRS 2021 Presentations on pulsed field ablation and left bundle branch pacing caught the eye of this electrophysiologist. However, being able to meet in person trumped all at the 2021 Heart Rhythm Society meeting.
  • Lessons From the Save of Christian Eriksen's Life The Danish soccer star went from 'being gone' to resuscitated. His widely watched experience teaches many lessons about improving care for sudden cardiac death, a major public health problem.
  • ACC 2021 Renal Denervation for Resistant Hypertension Is Not Back on Track The RADIANCE-HTN-TRIO presentation at the recent American College of Cardiology meeting has this cardiologist asking if mineralocorticoid inhibition might beat an invasive procedure for resistant hypertension.